BioXcel Therapeutics Inc (BTAI)vsUnited Therapeutics Corporation (UTHR)
BTAI
BioXcel Therapeutics Inc
$0.07
-37.11%
HEALTHCARE · Cap: $5.10M
UTHR
United Therapeutics Corporation
$593.31
-0.39%
HEALTHCARE · Cap: $25.07B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 429482% more annual revenue ($3.19B vs $742,000). UTHR leads profitability with a 38.6% profit margin vs 0.0%. UTHR earns a higher WallStSmart Score of 55/100 (C).
BTAI
Avoid27
out of 100
Grade: F
UTHR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+27.7%
Fair Value
$2.24
Current Price
$0.07
$2.17 discount
Margin of Safety
+2.4%
Fair Value
$487.71
Current Price
$593.31
$105.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 51.7% year-over-year
Conservative balance sheet, low leverage
Keeps 39 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.0%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
4.1% revenue growth
Earnings declined 20.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BTAI
The strongest argument for BTAI centers on Revenue Growth, Debt/Equity. Revenue growth of 51.7% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Altman Z-Score, Operating Margin. Profitability is solid with margins at 38.6% and operating margin at 29.0%.
Bear Case : BTAI
The primary concerns for BTAI are EPS Growth, Market Cap, Profit Margin.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
BTAI profiles as a hypergrowth stock while UTHR is a value play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.48 — expect wider price swings.
BTAI is growing revenue faster at 51.7% — sustainability is the question.
UTHR generates stronger free cash flow (126M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (55/100 vs 27/100), backed by strong 38.6% margins. BTAI offers better value entry with a 27.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioXcel Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?